BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Zhang GL, Sun X, Cao KX, Shang YW, Gong MX, Ma C, Nan N, Li JP, Yu MW, Yang GW, Wang XM. Gubenyiliu II Inhibits Breast Tumor Growth and Metastasis Associated with Decreased Heparanase Expression and Phosphorylation of ERK and AKT Pathways. Molecules 2017;22:E787. [PMID: 28505136 DOI: 10.3390/molecules22050787] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Zhang C, Wang N, Tan HY, Guo W, Li S, Feng Y. Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine. Integr Cancer Ther 2018;17:582-601. [PMID: 29807443 DOI: 10.1177/1534735418775828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
2 Wu YJ, Hsu WJ, Wu LH, Liou HP, Pangilinan CR, Tyan YC, Lee CH. Hinokitiol reduces tumor metastasis by inhibiting heparanase via extracellular signal-regulated kinase and protein kinase B pathway. Int J Med Sci 2020;17:403-13. [PMID: 32132875 DOI: 10.7150/ijms.41177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Fan Y, Ma Z, Zhao L, Wang W, Gao M, Jia X, Ouyang H, He J. Anti-tumor activities and mechanisms of Traditional Chinese medicines formulas: A review. Biomedicine & Pharmacotherapy 2020;132:110820. [DOI: 10.1016/j.biopha.2020.110820] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Sun X, Ma X, Li Q, Yang Y, Xu X, Sun J, Yu M, Cao K, Yang L, Yang G, Zhang G, Wang X. Anti‑cancer effects of fisetin on mammary carcinoma cells via regulation of the PI3K/Akt/mTOR pathway: In vitro and in vivo studies. Int J Mol Med 2018;42:811-20. [PMID: 29749427 DOI: 10.3892/ijmm.2018.3654] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
5 Park J, Jeong D, Song M, Kim B. Recent Advances in Anti-Metastatic Approaches of Herbal Medicines in 5 Major Cancers: From Traditional Medicine to Modern Drug Discovery. Antioxidants (Basel) 2021;10:527. [PMID: 33801741 DOI: 10.3390/antiox10040527] [Reference Citation Analysis]
6 Ji J, Shen T, Li Y, Liu Y, Shang Z, Niu Y. CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway. Oncol Rep 2021;45:921-32. [PMID: 33650660 DOI: 10.3892/or.2021.7920] [Reference Citation Analysis]
7 Wang S, Long S, Wu W. Application of Traditional Chinese Medicines as Personalized Therapy in Human Cancers. Am J Chin Med 2018;46:953-70. [DOI: 10.1142/s0192415x18500507] [Cited by in Crossref: 41] [Cited by in F6Publishing: 11] [Article Influence: 10.3] [Reference Citation Analysis]
8 Li QW, Zhang GL, Hao CX, Ma YF, Sun X, Zhang Y, Cao KX, Li BX, Yang GW, Wang XM. SANT, a novel Chinese herbal monomer combination, decreasing tumor growth and angiogenesis via modulating autophagy in heparanase overexpressed triple-negative breast cancer. J Ethnopharmacol 2021;266:113430. [PMID: 33011366 DOI: 10.1016/j.jep.2020.113430] [Reference Citation Analysis]